YARDLEY, Pa.--(BUSINESS WIRE)--OptiNose announced today it has been awarded $488,958 in grants under the U.S. government’s Qualifying Therapeutic Discovery Project (“QTDP”) program in support of the Company’s novel drug delivery technology. The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act, and provides a tax credit or grant equal to eligible costs and expenses for tax years 2009 and 2010.
